Tumor-Specific Major Histocompatibility-II Expression Predicts Benefit to Anti–PD-1/L1 Therapy in Patients With HER2-Negative Primary Breast CancerPaula I. González-Ericsson, Na Luo, Henry Gómez et al.|Clinical Cancer Research|2021Cited by 92
Quantitative MHC II protein expression levels in tumor epithelium to predict response to the PD1 inhibitor pembrolizumab in the I-SPY 2 Trial.Julia Wulfkuhle, Christina Yau, Denise M. Wolf et al.|Journal of Clinical Oncology|2019Cited by 11
Abstract CT144: Randomized phase II trial of preoperative fulvestrant with or without enzalutamide for ER+/Her2- breast cancerAnthony Elias, Jennifer K. Richer, Alyse Staley et al.|Cancer Research|2023Cited by 0
Abstract PS18-07: Differential odds of response in ILC versus IDC correlate with changes in the TIME in a phase II trial of pre-operative fulvestrant with or without enzalutamideJennifer K. Richer, Dexiang Gao, Anthony Elias et al.|Clinical Cancer Research|2025Cited by 0